Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
32.1M
-
Shares change
-
+1.01M
-
Total reported value, excl. options
-
$1.03B
-
Value change
-
+$31.2M
-
Put/Call ratio
-
2.69
-
Number of buys
-
27
-
Number of sells
-
-27
-
Price
-
$32.01
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q4 2020
67 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q4 2020.
ADC Therapeutics SA - Common Shares (ADCT) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.1M shares
of 124M outstanding shares and own 25.91% of the company stock.
Largest 10 shareholders include FMR LLC (7.76M shares), Redmile Group, LLC (6.76M shares), JPMORGAN CHASE & CO (2.99M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.97M shares), ALLIANCEBERNSTEIN L.P. (1.8M shares), Vantage Consulting Group Inc (1.68M shares), Grosvenor Holdings, L.L.C. (1.52M shares), BAKER BROS. ADVISORS LP (1.42M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.08M shares), and Polar Capital Holdings Plc (684K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.